SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 695.46+2.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2760)10/22/2019 2:14:41 AM
From: Miljenko Zuanic  Read Replies (2) of 3557
 
Lucentis 3Q ex-US sale of $500M (from Novartis) are down from 2Q, $536M, ~7%. 2Q 2018 Ex-US Lucentis sale was also weak relative to 2Q/4Q , so expectation are for *good* (bit conservative = flat) numbers from Bayer (10-30). Not that may do much to stock price (bears will always find reasons to negate, like future Eylea sale will suffer disastrous decline,...)...REGN need something very good and extraordinary from pipeline.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News